A Full-Service Contract Development and Manufacturing Organization (CDMO) is a company that provides comprehensive services across the entire drug development and manufacturing lifecycle, from early-stage development to commercial-scale production. These organizations offer a wide range of services to pharmaceutical and biotechnology companies, allowing them to outsource various aspects of drug development and manufacturing to external partners with specialized expertise and capabilities.
The global Full-Service CDMO market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淔ull-Service CDMO Industry Forecast鈥� looks at past sales and reviews total world Full-Service CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Full-Service CDMO sales for 2023 through 2029. With Full-Service CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Full-Service CDMO industry.
This Insight Report provides a comprehensive analysis of the global Full-Service CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Full-Service CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Full-Service CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Full-Service CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Full-Service CDMO.
United States market for Full-Service CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Full-Service CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Full-Service CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Full-Service CDMO players cover Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Full-Service CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
Segmentation by Application:
Pharmaceutical Company
Biotechnology Company
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
Segmentation by Application:
Pharmaceutical Company
Biotechnology Company
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Full-Service CDMO 麻豆原创 Size 2019-2030
2.1.2 Full-Service CDMO 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Full-Service CDMO by Country/Region, 2019, 2023 & 2030
2.2 Full-Service CDMO Segment by Type
2.2.1 API CDMO
2.2.2 FDF CDMO
2.2.3 Packaging CDMO
2.2.4 Clinical CDMO
2.3 Full-Service CDMO 麻豆原创 Size by Type
2.3.1 Full-Service CDMO 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Full-Service CDMO 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Full-Service CDMO Segment by Application
2.4.1 Pharmaceutical Company
2.4.2 Biotechnology Company
2.5 Full-Service CDMO 麻豆原创 Size by Application
2.5.1 Full-Service CDMO 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Full-Service CDMO 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Full-Service CDMO 麻豆原创 Size by Player
3.1 Full-Service CDMO 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Full-Service CDMO Revenue by Player (2019-2024)
3.1.2 Global Full-Service CDMO Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Full-Service CDMO Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Full-Service CDMO by Region
4.1 Full-Service CDMO 麻豆原创 Size by Region (2019-2024)
4.2 Global Full-Service CDMO Annual Revenue by Country/Region (2019-2024)
4.3 Americas Full-Service CDMO 麻豆原创 Size Growth (2019-2024)
4.4 APAC Full-Service CDMO 麻豆原创 Size Growth (2019-2024)
4.5 Europe Full-Service CDMO 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Full-Service CDMO 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Full-Service CDMO 麻豆原创 Size by Country (2019-2024)
5.2 Americas Full-Service CDMO 麻豆原创 Size by Type (2019-2024)
5.3 Americas Full-Service CDMO 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Full-Service CDMO 麻豆原创 Size by Region (2019-2024)
6.2 APAC Full-Service CDMO 麻豆原创 Size by Type (2019-2024)
6.3 APAC Full-Service CDMO 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Full-Service CDMO 麻豆原创 Size by Country (2019-2024)
7.2 Europe Full-Service CDMO 麻豆原创 Size by Type (2019-2024)
7.3 Europe Full-Service CDMO 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Full-Service CDMO by Region (2019-2024)
8.2 Middle East & Africa Full-Service CDMO 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Full-Service CDMO 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Full-Service CDMO 麻豆原创 Forecast
10.1 Global Full-Service CDMO Forecast by Region (2025-2030)
10.1.1 Global Full-Service CDMO Forecast by Region (2025-2030)
10.1.2 Americas Full-Service CDMO Forecast
10.1.3 APAC Full-Service CDMO Forecast
10.1.4 Europe Full-Service CDMO Forecast
10.1.5 Middle East & Africa Full-Service CDMO Forecast
10.2 Americas Full-Service CDMO Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Full-Service CDMO Forecast
10.2.2 Canada 麻豆原创 Full-Service CDMO Forecast
10.2.3 Mexico 麻豆原创 Full-Service CDMO Forecast
10.2.4 Brazil 麻豆原创 Full-Service CDMO Forecast
10.3 APAC Full-Service CDMO Forecast by Region (2025-2030)
10.3.1 China Full-Service CDMO 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Full-Service CDMO Forecast
10.3.3 Korea 麻豆原创 Full-Service CDMO Forecast
10.3.4 Southeast Asia 麻豆原创 Full-Service CDMO Forecast
10.3.5 India 麻豆原创 Full-Service CDMO Forecast
10.3.6 Australia 麻豆原创 Full-Service CDMO Forecast
10.4 Europe Full-Service CDMO Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Full-Service CDMO Forecast
10.4.2 France 麻豆原创 Full-Service CDMO Forecast
10.4.3 UK 麻豆原创 Full-Service CDMO Forecast
10.4.4 Italy 麻豆原创 Full-Service CDMO Forecast
10.4.5 Russia 麻豆原创 Full-Service CDMO Forecast
10.5 Middle East & Africa Full-Service CDMO Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Full-Service CDMO Forecast
10.5.2 South Africa 麻豆原创 Full-Service CDMO Forecast
10.5.3 Israel 麻豆原创 Full-Service CDMO Forecast
10.5.4 Turkey 麻豆原创 Full-Service CDMO Forecast
10.6 Global Full-Service CDMO Forecast by Type (2025-2030)
10.7 Global Full-Service CDMO Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Full-Service CDMO Forecast
11 Key Players Analysis
11.1 Lonza
11.1.1 Lonza Company Information
11.1.2 Lonza Full-Service CDMO Product Offered
11.1.3 Lonza Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Lonza Main Business Overview
11.1.5 Lonza Latest Developments
11.2 Catalent
11.2.1 Catalent Company Information
11.2.2 Catalent Full-Service CDMO Product Offered
11.2.3 Catalent Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Catalent Main Business Overview
11.2.5 Catalent Latest Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Information
11.3.2 Thermo Fisher Scientific Full-Service CDMO Product Offered
11.3.3 Thermo Fisher Scientific Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Thermo Fisher Scientific Main Business Overview
11.3.5 Thermo Fisher Scientific Latest Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Information
11.4.2 Samsung Biologics Full-Service CDMO Product Offered
11.4.3 Samsung Biologics Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Samsung Biologics Main Business Overview
11.4.5 Samsung Biologics Latest Developments
11.5 Fareva
11.5.1 Fareva Company Information
11.5.2 Fareva Full-Service CDMO Product Offered
11.5.3 Fareva Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Fareva Main Business Overview
11.5.5 Fareva Latest Developments
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Information
11.6.2 WuXi AppTech Full-Service CDMO Product Offered
11.6.3 WuXi AppTech Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 WuXi AppTech Main Business Overview
11.6.5 WuXi AppTech Latest Developments
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Information
11.7.2 WuXi Biologics Full-Service CDMO Product Offered
11.7.3 WuXi Biologics Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 WuXi Biologics Main Business Overview
11.7.5 WuXi Biologics Latest Developments
11.8 Siegfried
11.8.1 Siegfried Company Information
11.8.2 Siegfried Full-Service CDMO Product Offered
11.8.3 Siegfried Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Siegfried Main Business Overview
11.8.5 Siegfried Latest Developments
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Information
11.9.2 FUJIFILM Diosynth Biotechnologies Full-Service CDMO Product Offered
11.9.3 FUJIFILM Diosynth Biotechnologies Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
11.9.5 FUJIFILM Diosynth Biotechnologies Latest Developments
11.10 Asymchem
11.10.1 Asymchem Company Information
11.10.2 Asymchem Full-Service CDMO Product Offered
11.10.3 Asymchem Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Asymchem Main Business Overview
11.10.5 Asymchem Latest Developments
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Information
11.11.2 Pfizer CentreOne Full-Service CDMO Product Offered
11.11.3 Pfizer CentreOne Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Pfizer CentreOne Main Business Overview
11.11.5 Pfizer CentreOne Latest Developments
11.12 Delpharm
11.12.1 Delpharm Company Information
11.12.2 Delpharm Full-Service CDMO Product Offered
11.12.3 Delpharm Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Delpharm Main Business Overview
11.12.5 Delpharm Latest Developments
11.13 Recipharm
11.13.1 Recipharm Company Information
11.13.2 Recipharm Full-Service CDMO Product Offered
11.13.3 Recipharm Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Recipharm Main Business Overview
11.13.5 Recipharm Latest Developments
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Information
11.14.2 AGC Pharma Chemicals Full-Service CDMO Product Offered
11.14.3 AGC Pharma Chemicals Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 AGC Pharma Chemicals Main Business Overview
11.14.5 AGC Pharma Chemicals Latest Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Information
11.15.2 Boehringer Ingelheim Full-Service CDMO Product Offered
11.15.3 Boehringer Ingelheim Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Boehringer Ingelheim Main Business Overview
11.15.5 Boehringer Ingelheim Latest Developments
11.16 Vetter
11.16.1 Vetter Company Information
11.16.2 Vetter Full-Service CDMO Product Offered
11.16.3 Vetter Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Vetter Main Business Overview
11.16.5 Vetter Latest Developments
11.17 Curia
11.17.1 Curia Company Information
11.17.2 Curia Full-Service CDMO Product Offered
11.17.3 Curia Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Curia Main Business Overview
11.17.5 Curia Latest Developments
11.18 Aenova
11.18.1 Aenova Company Information
11.18.2 Aenova Full-Service CDMO Product Offered
11.18.3 Aenova Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Aenova Main Business Overview
11.18.5 Aenova Latest Developments
11.19 Porton
11.19.1 Porton Company Information
11.19.2 Porton Full-Service CDMO Product Offered
11.19.3 Porton Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Porton Main Business Overview
11.19.5 Porton Latest Developments
11.20 Piramal
11.20.1 Piramal Company Information
11.20.2 Piramal Full-Service CDMO Product Offered
11.20.3 Piramal Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 Piramal Main Business Overview
11.20.5 Piramal Latest Developments
11.21 Strides Pharma
11.21.1 Strides Pharma Company Information
11.21.2 Strides Pharma Full-Service CDMO Product Offered
11.21.3 Strides Pharma Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.21.4 Strides Pharma Main Business Overview
11.21.5 Strides Pharma Latest Developments
11.22 NextPharma
11.22.1 NextPharma Company Information
11.22.2 NextPharma Full-Service CDMO Product Offered
11.22.3 NextPharma Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.22.4 NextPharma Main Business Overview
11.22.5 NextPharma Latest Developments
11.23 Famar
11.23.1 Famar Company Information
11.23.2 Famar Full-Service CDMO Product Offered
11.23.3 Famar Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.23.4 Famar Main Business Overview
11.23.5 Famar Latest Developments
11.24 Jubilant
11.24.1 Jubilant Company Information
11.24.2 Jubilant Full-Service CDMO Product Offered
11.24.3 Jubilant Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.24.4 Jubilant Main Business Overview
11.24.5 Jubilant Latest Developments
11.25 Alcami
11.25.1 Alcami Company Information
11.25.2 Alcami Full-Service CDMO Product Offered
11.25.3 Alcami Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.25.4 Alcami Main Business Overview
11.25.5 Alcami Latest Developments
11.26 Euroapi
11.26.1 Euroapi Company Information
11.26.2 Euroapi Full-Service CDMO Product Offered
11.26.3 Euroapi Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.26.4 Euroapi Main Business Overview
11.26.5 Euroapi Latest Developments
11.27 Eurofins
11.27.1 Eurofins Company Information
11.27.2 Eurofins Full-Service CDMO Product Offered
11.27.3 Eurofins Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.27.4 Eurofins Main Business Overview
11.27.5 Eurofins Latest Developments
11.28 Avid Bioservices
11.28.1 Avid Bioservices Company Information
11.28.2 Avid Bioservices Full-Service CDMO Product Offered
11.28.3 Avid Bioservices Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.28.4 Avid Bioservices Main Business Overview
11.28.5 Avid Bioservices Latest Developments
11.29 BioVectra
11.29.1 BioVectra Company Information
11.29.2 BioVectra Full-Service CDMO Product Offered
11.29.3 BioVectra Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.29.4 BioVectra Main Business Overview
11.29.5 BioVectra Latest Developments
11.30 CPL
11.30.1 CPL Company Information
11.30.2 CPL Full-Service CDMO Product Offered
11.30.3 CPL Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.30.4 CPL Main Business Overview
11.30.5 CPL Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
